logo
Should You Buy Take-Two Stock Around $235?

Should You Buy Take-Two Stock Around $235?

Yahoo16-07-2025
Take-Two stock is rising on high sales expectations for an upcoming release.
Analysts expect sales of "Grand Theft Auto VI" to lift Take-Two's revenue by 52% in fiscal 2027.
Strong sales of add-on content and in-game spending could lead to significantly higher margins and earnings.
10 stocks we like better than Take-Two Interactive Software ›
Investors are keen on Take-Two Interactive's (NASDAQ: TTWO) prospects with the blockbuster release of Grand Theft Auto VI less than a year away. The Grand Theft Auto franchise has become a cornerstone of pop culture and has been one of the best-selling video game series of all time.
Scheduled to debut on May 26, 2026, the newest installment will tap into a huge fanbase that's anxious to jump into a new adventure -- it has been 12 years since the previous release of Grand Theft Auto V. The featured song in the release trailer for the upcoming title saw an 182,000% increase in the number of streams on Spotify, while the trailer itself was viewed over 475 million times in the first 24 hours.
Anticipation for the game is sky-high, and Take-Two stock is up 27% year to date, as of this writing. Though the new release is still a year away, the substantial windfall it can offer Take-Two's business justifies buying the stock now, and growth estimates from Wall Street analysts seem to echo this sentiment. Here's what you need to know.
From a valuation perspective, Take-Two stock is clearly priced for growth. It currently trades at a forward price-to-earnings (P/E) ratio of 87 based on earnings estimates for the current fiscal year (ending Mar. 31, 2026). That multiple drops to 25 for fiscal 2027, based not just on expectations for Grand Theft Auto (GTA) but also strong sales across Take-Two's large catalogue of titles.
Take-Two has two upcoming releases this year that should also deliver strong sales: Borderlands 4 and Mafia: The Old Country. Borderlands is the bigger franchise, with the previous installment selling 22 million units.
Management's fiscal 2026 outlook calls for net bookings to grow roughly 5% over fiscal 2025, to a range $5.9 billion to $6.0 billion. Nearly half of bookings are expected to come from Zynga's mobile titles, with another 39% coming from the 2K label and 16% from Rockstar Games, which includes sales of the current GTA title.
Fiscal 2027 will be the first year to include sales of GTA VI. Management doesn't offer specific revenue guidance this far out, but Wall Street analysts currently expect revenue to grow 52% over fiscal 2026 to reach a record $9.1 billion.
For perspective, the previous release grew revenue 98% in Take-Two's fiscal 2014, and it supported a decade of growth for the business.
Take-Two could be looking at a strong five-year stretch of growth, at a minimum. Wall Street analysts currently project revenue will reach $10.9 billion by fiscal 2030, implying a five-year compound annual growth rate of 14%.
The company is executing a long-term growth strategy that extends beyond GTA VI as well. It has 25 titles planned for release through fiscal 2028, including releases for existing franchises, five sports simulation games, and four mobile titles. This should further pad its top-line momentum.
What's really going to move the stock is earnings. Three quarters of Take-Two's bookings come from recurrent consumer spending, including virtual currency, add-on content updates to existing games, and in-game advertising. This revenue is very accretive to margins and earnings, and Take-Two has mastered the art of keeping players spending time with GTA V for the last decade through Grand Theft Auto Online. GTA VI should be able to drive similar growth in recurrent consumer spending.
Analysts expect Take-Two's adjusted earnings to grow at an annualized rate of 39% over the next five years, reaching $16.03 per share. If the stock is still trading at 25 times earnings, that would put the share price at $400. Even allowing for some margin of error in analysts' estimates, this top video game stock still offers upside from the current $234 share price.
However, investors need to keep in mind that release dates for games are not set in stone. GTA VI was originally scheduled to release this year, but it was pushed back to give the developers more time to polish the game. Given this uncertainty, which tends to result in greater volatility for the stock, I would keep any position in Take-Two small and then buy more shares on any dips.
Before you buy stock in Take-Two Interactive Software, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Take-Two Interactive Software wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!*
Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of July 14, 2025
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Spotify Technology and Take-Two Interactive Software. The Motley Fool has a disclosure policy.
Should You Buy Take-Two Stock Around $235? was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment
Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment

Yahoo

time12 minutes ago

  • Yahoo

Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment

Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30, Leerink Partners raised its price target for the stock to $75 from $73. The research firm also reiterated an 'Outperform' rating on the stock. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. The research firm hiked its price target following positive Phase III trial results from the FORTITUDE-101 study. The study was evaluating bemarituzumab as a first-line FGFR2B-positive gastric cancer treatment. The candidate drug, developed in partnership with Amgen, met its primary endpoint while demonstrating a significant and clinically meaningful overall survival benefit compared to placebo plus chemotherapy. Following the positive results, Zai Labs plans a second Phase III trial, FORTITUDE-102, which will evaluate bemarituzumab in combination with chemotherapy and nivolumab. The company expects top-line data in the second half of the year that will affirm the candidate drug as a first-line treatment for gastric cancer. It also plans to file for regulatory approval in China following the positive results. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects

Yahoo

time17 minutes ago

  • Yahoo

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects

Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a 'Neutral' rating on the stock and increased its price target to $62 from $61. A pharmacist preparing a dose of an immuno-oncology agent for research use. The price hike comes as UBS expects higher sales for Incyte's Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26. UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company's second-quarter earnings call to provide clarity on the company's strategic direction. The company's pipeline has already received a boost following the FDA's extension of the review for ruxolitinib cream for pediatric atopic dermatitis. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.

Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook

Yahoo

time17 minutes ago

  • Yahoo

Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook

Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 8, Truist Securities reiterated a 'Buy' rating on the stock and increased its price target to $46 from $45. A doctor in a hospital consulting with a cancer patient about immuno-oncology therapy. According to Truist Securities, the current valuation does not depict the company's fair value. That's because it boasts an established revenue and solid pipeline potential. The price target adjustment underscores Truist Securities' confidence about Genmab's revenue outlook for 2025. The research firm is confident about the company's cancer drug Darzalex as prescription data indicates 10% quarter-over-quarter growth in Q2. The firm is also bullish about the company's other products, including Epkinly and Kesimpta. Truist Securities has also expressed confidence in Genmab's pipeline assets, including Rina-S, Acasun, and Gen1042, which it believes are undervalued. Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. It utilizes advanced antibody technologies, such as DuoBody and HexaBody, to create next-generation therapeutic antibodies. While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store